RT @Lena_Kutscher: I’m excited to share our latest work investigating the underlying biology and tumor mechanisms of Group 3/4 medulloblast…
Medulloblastoma oncogene aberrations are not involved in tumor initiation, but essential for disease progression and therapy resistance: Despite recent advances in understanding disease biology, treatment of Group 3/4 medulloblastoma remains a… https://t.c
RT @Lena_Kutscher: I’m excited to share our latest work investigating the underlying biology and tumor mechanisms of Group 3/4 medulloblast…
RT @Lena_Kutscher: I’m excited to share our latest work investigating the underlying biology and tumor mechanisms of Group 3/4 medulloblast…
RT @Lena_Kutscher: I’m excited to share our latest work investigating the underlying biology and tumor mechanisms of Group 3/4 medulloblast…
RT @Lena_Kutscher: I’m excited to share our latest work investigating the underlying biology and tumor mechanisms of Group 3/4 medulloblast…
RT @Lena_Kutscher: I’m excited to share our latest work investigating the underlying biology and tumor mechanisms of Group 3/4 medulloblast…
RT @biorxiv_cancer: Medulloblastoma oncogene aberrations are not involved in tumor initiation, but essential for disease progression and th…
Tiny boost of study #2: we found that in medulloblastomas the initiating somatic events are large scale chromosomal aberrations, while single oncogene aberrations such as MYC/N amplifcations arise late and typically subclonal! Check both manuscripts for m
RT @Lena_Kutscher: In the second paper, we use a subset of tumors from our single-cell atlas, focusing on Group 3/4 tumor samples where the…
RT @Lena_Kutscher: In the second paper, we use a subset of tumors from our single-cell atlas, focusing on Group 3/4 tumor samples where the…
@DKFZ These results are important for understanding tumor evolution and modeling, and may be important for early detection. We’re looking forward to any feedback and thoughts about our manuscripts! https://t.co/N6hPrC5ArR
In the second paper, we use a subset of tumors from our single-cell atlas, focusing on Group 3/4 tumor samples where the oncogenes MYC, MYCN, or PRDM6 are amplified/overexpressed, to identify the clonal lineages and initiation timing within these tumors.
I’m excited to share our latest work investigating the underlying biology and tumor mechanisms of Group 3/4 medulloblastoma. Our collaborative team @KiTZ includes Stefan Pfister, @mad_kook, Piyush Joshi, Tamina Stelzer, @VeKoerber https://t.co/Uku2c28ODg
Medulloblastoma oncogene aberrations are not involved in tumor initiation, but essential for disease progression and therapy resistance https://t.co/jsqXq4KPD7 #biorxiv_cancer